CapeDx is the most comprehensive cancer genomic test in the world.
The service is patient-focused, matching individuals to the latest options in treatment including approved drugs and drugs in clinical trials.
genomiQa helps private and public health systems to provide comprehensive cancer genomics for their patients.
genomiQa can deliver CapeDx as a SaaS (Software as a Service) pipeline to support health service providers and genomics companies to deploy whole genome sequence analysis and variant annotation.
Available for research use. NATA accreditation expected in Australia later in 2021.